Overview
Chromozoom is redefining personal health by combining DNA analysis, microbiome testing, and personalized supplementation into a single, accessible service. Their mission is to translate complex biological data into actionable lifestyle changes.
WDF serves as Chromozoom’s primary engineering partner, responsible for the entire digital ecosystem. This involves more than just building an app; we architected and operate the complete infrastructure that connects physical laboratory kits, a custom-built e-commerce platform, and a secure results dashboard. From the "MagicBox" data engine to the customer-facing mobile and web apps, WDF ensures that high-volume biological data is processed securely and presented simply.
The Business Challenge
Building a direct-to-consumer genetics brand requires solving a contradiction: the platform needs the marketing agility of a retail e-shop while maintaining the rigorous security and stability of a medical data vault.
Chromozoom needed to sell diverse products—from DNA kits to recurring personalized vitamin subscriptions—and seamlessly link those purchases to complex scientific reports. The challenge was to create a "Unified Identity" where a user logs in once to buy a test, view their results, and order supplements, even though these actions require fundamentally different technical architectures. Furthermore, as the company expanded into microbiome testing and personalized supplements, the system needed to handle dynamic data structures without disrupting the user experience.
Our Role
WDF took full ownership of the technology stack, acting as the architect and operator of Chromozoom’s infrastructure. We designed a solution that separates concerns without fragmenting the user journey.
We built a custom e-commerce solution to handle the complexities of product bundles and CRM integration, while simultaneously developing a high-security application layer for processing genetic results. Our role extends to the core of the business logic: we are currently engineering "MagicBox 2.0," a next-generation engine designed to process bio-data faster and more securely, ensuring the platform is ready for mass-market scale.
